LJPC
La Jolla Pharmaceutical Co.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
Market Cap: 155 Million
Primary Exchange: NASDAQ
Website: lajollapharmaceutical.com
Shares Outstanding: 24.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.4351943021081673
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 2026 trading days
From: 2015-09-08 To: 2022-08-19
Lowest Point:
La Jolla: A Cinderella Bioscience Innovator
via: SeekingAlpha at 2019-06-11 09:11:57:000
Successful Investing takes time, discipline and patience. No matter how great the talent or effort, some things just take time: You can't produce a baby in one month by getting nine women pregnant. - Warren Buffett As much as I enjoy a good comeback story like Rocky Balboa, I'm highly enth… read more...
La Jolla: A Cinderella Bioscience Innovator
via: SeekingAlpha at 2019-06-11 09:11:57:000
Successful Investing takes time, discipline and patience. No matter how great the talent or effort, some things just take time: You can't produce a baby in one month by getting nine women pregnant. - Warren Buffett As much as I enjoy a good comeback story like Rocky Balboa, I'm highly enth… read more...
La Jolla: A Cinderella Bioscience Innovator
via: SeekingAlpha at 2019-06-11 09:11:57:000
Successful Investing takes time, discipline and patience. No matter how great the talent or effort, some things just take time: You can't produce a baby in one month by getting nine women pregnant. - Warren Buffett As much as I enjoy a good comeback story like Rocky Balboa, I'm highly enth… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-06-10 08:51:13:000
Gainers: Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2014-01-14 | 50.0 | 1.0 | 50.0 |